These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19243284)

  • 1. S-1: a promising new oral fluoropyrimidine derivative.
    Saif MW; Syrigos KN; Katirtzoglou NA
    Expert Opin Investig Drugs; 2009 Mar; 18(3):335-48. PubMed ID: 19243284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
    Schöffski P
    Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
    Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
    Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of S-1].
    Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
    Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
    Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
    Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
    Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.
    Shirasaka T; Yamamitsu S; Tsuji A; Taguchi T
    Invest New Drugs; 2000 Nov; 18(4):315-29. PubMed ID: 11081568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
    Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
    Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
    Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
    Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
    Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S-1 for the treatment of gastrointestinal cancer.
    Satoh T; Sakata Y
    Expert Opin Pharmacother; 2012 Sep; 13(13):1943-59. PubMed ID: 22860709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.